SpringWorks Therapeutics (SWTX) Projected to Post Earnings on Thursday

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) will likely be releasing its Q1 2025 earnings data before the market opens on Thursday, May 1st. Analysts expect SpringWorks Therapeutics to post earnings of ($0.79) per share and revenue of $66.93 million for the quarter.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last issued its earnings results on Thursday, February 20th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.38). SpringWorks Therapeutics had a negative net margin of 134.73% and a negative return on equity of 46.74%. The company had revenue of $61.55 million for the quarter, compared to analysts' expectations of $60.53 million. On average, analysts expect SpringWorks Therapeutics to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

SpringWorks Therapeutics Trading Up 3.2 %

Shares of NASDAQ SWTX traded up $1.45 during trading hours on Monday, reaching $46.17. The stock had a trading volume of 71,874,130 shares, compared to its average volume of 1,754,294. SpringWorks Therapeutics has a 52-week low of $28.21 and a 52-week high of $62.00. The firm has a market cap of $3.46 billion, a price-to-earnings ratio of -13.27 and a beta of 0.79. The business's fifty day moving average price is $46.20 and its two-hundred day moving average price is $40.64.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on SWTX shares. Guggenheim dropped their target price on SpringWorks Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a research note on Wednesday, January 8th. Wedbush restated a "neutral" rating and set a $47.00 price objective (down previously from $81.00) on shares of SpringWorks Therapeutics in a report on Monday. Barclays reiterated an "equal weight" rating and issued a $47.00 target price (down from $63.00) on shares of SpringWorks Therapeutics in a research note on Monday. Evercore ISI upped their price target on shares of SpringWorks Therapeutics from $60.00 to $65.00 and gave the company an "outperform" rating in a research note on Wednesday, February 12th. Finally, HC Wainwright restated a "buy" rating and issued a $74.00 target price on shares of SpringWorks Therapeutics in a research note on Friday, February 21st. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $63.17.

Insider Buying and Selling at SpringWorks Therapeutics

In other SpringWorks Therapeutics news, CEO Saqib Islam sold 48,000 shares of the firm's stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $53.30, for a total value of $2,558,400.00. Following the sale, the chief executive officer now directly owns 1,002,502 shares of the company's stock, valued at approximately $53,433,356.60. This trade represents a 4.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Badreddin Edris sold 30,000 shares of the stock in a transaction on Monday, February 10th. The shares were sold at an average price of $53.13, for a total transaction of $1,593,900.00. Following the transaction, the chief operating officer now directly owns 189,712 shares in the company, valued at approximately $10,079,398.56. The trade was a 13.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 440,766 shares of company stock valued at $24,402,956. 7.83% of the stock is owned by insiders.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.